Abstract:Sarah-Eve Lemay 1 , Steeve Provencher 1,2 , Sébastien Bonnet 1,2 , François Potus 1,2 , Olivier Boucherat 1,2 1 Pulmonary Hypertension Research Group, Québec Heart and Lung Institute Research Centre, Québec City, QC, Canada; 2 Department of Medicine, Laval University, Québec City, QC, Canada Comment on: Tai YY, Yu Q, Tang Y, et al . Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension. Sci Transl Med 2024;16:eadd2029. Keywords: Pulmonary arterial hypertension (PAH); vascular remodeling; long non-coding RNA (lncRNA); hypoxia; pulmonary artery endothelial cells (PAECs) Submitted Mar 11, 2024. Accepted for publication Apr 28, 2024. Published online May 28, 2024. doi: 10.21037/atm-24-54 Pulmonary hypertension (PH) encompasses an heterogenous group of disorders, all hemodynamically defined by a mean pulmonary artery (PA) pressure >20 mmHg and characterized by endothelial injury and dysfunction, excessive vasoconstriction, and abnormal vascular remodeling of small PAs (1,2). These changes cause an increase in pulmonary vascular resistance, which ultimately results in right ventricular failure (2). Patients with PH are classified into five groups based upon etiology and mechanism. Although uncommon compared to other forms of PH, pulmonary arterial hypertension (PAH; group 1 PH) is the most severe and best studied subtype (3). Additionally, PH frequently complicates the clinical course of patients with lung diseases and/or hypoxemia, such as chronic obstructive pulmonary disease and interstitial lung disease (group 3 PH). This comorbidity exacerbates the already elevated morbidity and mortality rates associated with these conditions (4). Despite intense research endeavors and Food and Drug Administration (FDA)-approved drugs that mainly target pulmonary vasoconstriction (2,3,5), the prognosis of patients with group 1 and group 3 PH remains poor, emphasizing the urgent need for a better understanding of the molecular mechanisms leading to vascular remodeling. Activation of hypoxia-inducible factors (HIFs) is a hallmark of various subtypes of PH and a driving force in reprogramming the cellular metabolic and epigenetic landscape of PA resident cells (6,7). Among the different oxygen-sensitive alpha subunits, HIF-2α has emerged to play a predominant role in mediating PA endothelial cell (PAEC) proliferation contributing to the development of occlusive intimal/neointimal lesions. Notably, inactivation of HIF-2α targeted to the pulmonary endothelium has been shown to confer protection against chronic hypoxia-induced PH to a greater extent compared to mice with pulmonary endothelial deletion of HIF-1α (8,9). Additionally, pharmacological inhibition of HIF-2α was reported to improve pulmonary vascular remodeling and hemodynamics in several preclinical models of established PH (10). Although HIF-2α is a central protagonist of pulmonary vascular remodeling, the molecular mechanisms mediating its effects and accounting for its upregulation in PAECs remain poorly characterized. Similarly, although the implication of epigenetic changes, such as histone modifications and non-coding RNAs, is gaining increasing attention at the forefront of PH research field, they are still at the beginning. In their recent article published in Science Translational Medicine (11) (summarized in Figure 1 ), Pr. Chan and colleagues provide comprehensive and compelling insights into the intricate relationship between hypoxia and epigenetic events, and its critical impact on metabolic reprogramming that favors PAEC proliferation. As a starting point, the authors identified a long non-coding RNA (lncRNA) called E22 , which was upregulated in the lungs of mice in which PH was induced by the combined exposure to hypoxia and a VEGF receptor antagonist. Interest in this lncRNA was piqued by its conserved syntenic location, positioned head-to-head with the histone lysine N-methyltransferase 2E ( KMT2E ) gene and its partially conserved sequence with human KMT2E-AS1 . Subsequent experiments showed that the increase in E22 , KMT2E-AS1 , and KMT2E transcripts was mainly detected in PAEC of remodeled PAs from both group 1 and group 3 PH patients and PH animal models with preferential nuclear localization. Furthermore, using a bidirectional approach in cultured endothelial cells, HIF-2α was identified as a key regulator of the lncRNA-KMT2E pair. Indeed, depletion of HIF-2α was found to abolish the up-regulation of KMT2E-AS1 and KMT2E transcripts under hypoxia, whereas forced expression of a constitutively active form of HIF-2α in normoxic cells led to opposite effects. Since its nuclear-enriched localization implies a role in chromatin remodeling and trans -Abstract Truncated-

PPARγ/ETV2 axis regulates endothelial‐to‐mesenchymal transition in pulmonary hypertension

Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension.

Overexpressed pigment epithelium-derived factor alleviates pulmonary hypertension in two rat models induced by monocrotaline and SU5416/hypoxia

Endothelial HIF-2α Contributes to Severe Pulmonary Hypertension Due to Endothelial-to-mesenchymal Transition.

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

A HIF-2α-dependent KMT2E-AS1/KMT2E axis orchestrates endothelial epigenetic and metabolic dysfunction in pulmonary hypertension

Prolyl-4 Hydroxylase 2 (PHD2) Deficiency in Endothelial Cells and Hematopoietic Cells Induces Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension in Mice and Humans Through Hypoxia-Inducible Factor-2α

Updated perspective of EPAS1 and the role in pulmonary hypertension

Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension

Endothelial Heterogeneity in the Response to Autophagy Drives Small Vessel Muscularization in Pulmonary Hypertension

Abstract 17370: Activation of Endothelial GCN2 Kinase Contributes to Pulmonary Vascular Remodeling and Pulmonary Arterial Hypertension

SOX17 Prevents Endothelial-Mesenchymal Transition of Pulmonary Arterial Endothelial Cells in Pulmonary Hypertension through Mediating TGF-β/Smad2/3 Signaling

Abstract 9804: Overexpression of Pericyte Hif2a Exacerbates Hypoxia Induced Pulmonary Hypertension and Right Ventricular Hypertrophy

Abstract 9770: Endothelial Loss of Amphiregulin Drives Inflammation and Endothelial Apoptosis in Pulmonary Hypertension

Endothelial and Smooth Muscle Cell Interaction Via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension

Allele-specific control of rodent and human lncRNA KMT2E-AS1 promotes hypoxic endothelial pathology in pulmonary hypertension

Estrogen Oppositely Regulates Pulmonary Hypertension via METTL3/PFKFB3 Under Normoxia and Hypoxia

Loss of Amphiregulin drives inflammation and endothelial apoptosis in pulmonary hypertension

Endothelial-to-mesenchymal transition: Pathogenesis and therapeutic targets for chronic pulmonary and vascular diseases

Dual PEDF and HGF Overexpression: A New Therapy for Pulmonary Hypertension

Opposite alterations of endothelin-1 in lung and pulmonary artery mirror gene expression of bone morphogenetic protein receptor 2 in experimental pulmonary hypertension